Marks Group Wealth Management Inc Sells 858 Shares of Genmab A/S (NASDAQ:GMAB)

Marks Group Wealth Management Inc cut its stake in Genmab A/S (NASDAQ:GMAB) by 6.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,911 shares of the company’s stock after selling 858 shares during the period. Marks Group Wealth Management Inc’s holdings in Genmab A/S were worth $379,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. HBK Sorce Advisory LLC boosted its position in shares of Genmab A/S by 4.8% during the 3rd quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock worth $322,000 after acquiring an additional 419 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Genmab A/S by 86.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after buying an additional 498 shares during the last quarter. Park Place Capital Corp raised its stake in Genmab A/S by 12.3% during the fourth quarter. Park Place Capital Corp now owns 4,891 shares of the company’s stock worth $156,000 after buying an additional 535 shares during the last quarter. Grandfield & Dodd LLC raised its stake in Genmab A/S by 2.3% during the fourth quarter. Grandfield & Dodd LLC now owns 25,558 shares of the company’s stock worth $814,000 after buying an additional 565 shares during the last quarter. Finally, Pinnacle Bancorp Inc. increased its stake in Genmab A/S by 315.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock valued at $27,000 after purchasing an additional 638 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GMAB has been the topic of several analyst reports. Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. BMO Capital Markets upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $46.00 to $48.00 in a research note on Friday, February 23rd. Truist Financial reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Tuesday, March 26th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, April 4th. Finally, Citigroup cut shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Genmab A/S currently has a consensus rating of “Hold” and an average price target of $48.50.

Genmab A/S Stock Performance

Genmab A/S stock opened at $28.64 on Wednesday. Genmab A/S has a 1 year low of $26.32 and a 1 year high of $42.72. The company’s fifty day moving average price is $29.45 and its 200 day moving average price is $30.15. The stock has a market capitalization of $18.94 billion, a P/E ratio of 29.75, a P/E/G ratio of 2.08 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.02. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. The company had revenue of $675.29 million for the quarter, compared to analysts’ expectations of $678.14 million. Sell-side analysts predict that Genmab A/S will post 1.06 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.